# BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma

> **NCT06854003** · PHASE2 · RECRUITING · sponsor: **Christine Ryan** · enrollment: 60 (estimated)

## Conditions studied

- Mantle Cell Lymphoma
- Lymphoma

## Interventions

- **DRUG:** Bendamustine
- **DRUG:** Rituximab
- **DRUG:** Cytarabine
- **DRUG:** Zanubrutinib
- **DRUG:** Sonrotoclax

## Key facts

- **NCT ID:** NCT06854003
- **Lead sponsor:** Christine Ryan
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-22
- **Primary completion:** 2029-11-01
- **Final completion:** 2039-11-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-02-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06854003

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06854003, "BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06854003. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*